Dr. Juan Yang 杨娟
Chief Physician
Department of Gynecologic Oncology, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of gynecologic malignancies, with a focus on surgical management of ovarian, cervical, and endometrial cancers.
Dr. Yang holds an MD and serves as Chief Physician. A visiting scholar at MD Anderson Cancer Center, Dr. Yang emphasizes individualized care. Research includes four provincial Natural Science Foundation projects and participation in multiple national projects. Publications include 10 SCI-indexed articles and multiple papers in core journals.
Professional roles
- Vice Chair, Gynecologic Oncology Professional Committee, Hunan Anti-Cancer Association
- Member, Hunan Preventive Medicine Maternal and Child Health Hospital Society
- Member, Gynecologic Oncology Committee, China Geriatrics Society
Name order: in Chinese the family name comes first (Yang Juan). Papers usually list the name as Juan Yang or Yang J.
Selected publications
13 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Biochem Mol Toxicol, 2025 (first author): ARL4C depletion suppresses the resistance of ovarian cancer to Carboplatin by disrupting cholesterol transport and autophagy via Notch-RBP-Jκ-H3K4Me3-OSBPL5. PubMed 41378627
- Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2025 (senior author): Effects of lncRNA RP11-499E18.1 on the malignant biological behavior of ovarian cancer cells. PubMed 40457785
- Hum Exp Toxicol, 2022 (first author): ARL4C depletion suppresses the resistance of ovarian cancer to carboplatin by disrupting cholesterol transport and autophagy via notch-RBP-Jκ-H3K4Me3-OSBPL5. PubMed 36366750
- Front Cell Dev Biol, 2021 (first author): LncRNA RP11-499E18.1 Inhibits Proliferation, Migration, and Epithelial-Mesenchymal Transition Process of Ovarian Cancer Cells by Dissociating PAK2-SOX2 Interaction. PubMed 34621737
- Aging (Albany NY), 2020 (first author): LINC00452 promotes ovarian carcinogenesis through increasing ROCK1 by sponging miR-501-3p and suppressing ubiquitin-mediated degradation. PubMed 33168781
- Biomed Pharmacother, 2016 (first author): Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer. PubMed 27780136
- Biomed Pharmacother, 2016 (first author): MiR-125a regulates ovarian cancer proliferation and invasion by repressing GALNT14 expression. PubMed 27133078
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion